Intracranial mesenchymal tumor, FET::CREB fusion-positive in the lateral ventricle

Authors:

Abstract
Intracranial mesenchymal tumor, FET::CREB fusion-positive, is a recently recognized provisional entity in the 2021 WHO Classification of Tumors of the Central Nervous System.1 These are mesenchymal, nonmeningothelial tumors, with a wide morphologic spectrum.2–4 Mitotic activity is usually low (2). Architectural patterns vary from syncytial or sheet-like to reticular cord-like structures. The stroma can be collagenous or myxoid. A fusion between a FET RNA-binding protein family gene (EWSR1 and FUS) and a member of the CREB family of transcription factors (ATF1, CREB, and CREM) is diagnostic.1 Specifically, EWSR1::CREB fusions have been shown in angiomatoid fibrous histiocytoma and clear cell sarcoma.5,6 Prior nosological designations “intracranial myxoid variant of angiomatoid fibrous histiocytoma,” “intracranial myxoid mesenchymal tumor with EWSR1::CREB family gene fusions” are no longer recommended for this entity.7,8 We report a case of intracranial mesenchymal tumor, FET::CREB fusion-positive, in lateral ventricle of an adult patient.
Funding Information
  • National Cancer Institute
  • National Institutes of Health (K08CA241651)

This publication has 15 references indexed in Scilit: